RT Journal Article
SR Electronic
T1 Longitudinal serologic and viral testing post–SARS-CoV-2 infection and post-receipt of mRNA COVID-19 vaccine in a nursing home cohort—Georgia, October 2020‒April 2021
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.28.21268458
DO 10.1101/2021.12.28.21268458
A1 Tobolowsky, Farrell A.
A1 Waltenburg, Michelle A.
A1 Moritz, Erin D.
A1 Haile, Melia
A1 DaSilva, Juliana C.
A1 Schuh, Amy J.
A1 Thornburg, Natalie J.
A1 Westbrook, Adrianna
A1 McKay, Susannah L.
A1 LaVoie, Stephen P.
A1 Folster, Jennifer M.
A1 Harcourt, Jennifer L.
A1 Tamin, Azaibi
A1 Stumpf, Megan M.
A1 Mills, Lisa
A1 Freeman, Brandi
A1 Lester, Sandra
A1 Beshearse, Elizabeth
A1 Lecy, Kristin D.
A1 Brown, Laura G.
A1 Fajardo, Geroncio
A1 Negley, Jeanne
A1 McDonald, L. Clifford
A1 Kutty, Preeta K.
A1 Brown, Allison C.
A1 ,
YR 2022
UL http://medrxiv.org/content/early/2022/01/01/2021.12.28.21268458.abstract
AB Importance There are limited data describing SARS-CoV-2–specific immune responses and their durability following infection and vaccination in nursing home residents.Objective To evaluate the quantitative titers and durability of binding antibodies detected after SARS-CoV-2 infection and subsequent COVID-19 vaccination.Design A prospective longitudinal evaluation included nine visits over 150 days; visits included questionnaire administration, blood collection for serology, and paired anterior nasal specimen collection for testing by BinaxNOW™ COVID-19 Ag Card (BinaxNOW), reverse transcription polymerase chain reaction (RT-PCR), and viral culture.Setting A nursing home during and after a SARS-CoV-2 outbreak.Participants 11 consenting SARS-CoV-2–positive nursing home residents.Main Outcomes and Measures SARS-CoV-2 testing (BinaxNOW™, RT-PCR, viral culture); quantitative titers of binding SARS-CoV-2 antibodies post-infection and post-vaccination (beginning after the first dose of the primary series).Results Of 10 participants with post-infection serology results, 9 (90%) had detectable Pan-Ig, IgG, and IgA antibodies and 8 (80%) had detectable IgM antibodies. At first antibody detection post-infection, two-thirds (6/9, 67%) of participants were RT-PCR–positive but none were culture positive. Ten participants received vaccination; all had detectable Pan-Ig, IgG, and IgA antibodies through their final observation ≤90 days post-first dose. Post-vaccination geometric means of IgG titers were 10–200-fold higher than post-infection.Conclusions and Relevance Nursing home residents in this cohort mounted robust immune responses to SARS-CoV-2 post-infection and post-vaccination. The augmented antibody responses post-vaccination are potential indicators of enhanced protection that vaccination may confer on previously infected nursing home residents.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo financial support was provided relevant to this article.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This evaluation was reviewed by the National Center for Emerging and Zoonotic Infectious Diseases Human Studies Coordinator at the Centers for Disease Control and Prevention (CDC) and was determined to be non-research public health surveillance as defined in 45 CF 46.102. It was determined that ethical review by the CDC Human Research Protection Office and IRB review was not required. All necessary participant consent was obtained.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData produced in the present study are available upon reasonable request to the authors.